What is the Tymlos label?
The Tymlos label details important information for healthcare professionals and patients regarding the use of abaloparatide for injection, sold under the brand name Tymlos. It outlines the drug's indications, dosage, administration, contraindications, warnings, precautions, adverse reactions, drug interactions, and clinical trial data. The label serves as the official prescribing information for Tymlos.
What is Tymlos used to treat?
Tymlos is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture. In postmenopausal women with osteoporosis, the risk of vertebral and non-vertebral fractures has been shown.
What is the recommended dosage for Tymlos?
The recommended dose of Tymlos is 80 mcg administered subcutaneously once daily [1].
How is Tymlos administered?
Tymlos is administered as a subcutaneous injection once daily. Patients should be trained on proper injection techniques.
What are the contraindications for Tymlos?
Tymlos is contraindicated in patients with known hypersensitivity to abaloparatide or any of its excipients. It is also contraindicated in patients with Paget's disease of bone, unexplained elevations of alkaline phosphatase, or prior external beam radiation therapy or implantation of radioactive isotopes into the pelvis or lumbar spine. Additionally, it is contraindicated in patients with pre-existing hypercalcemia or metabolic bone diseases other than primary osteoporosis, including}}$.
What are the potential risks and warnings associated with Tymlos?
Osteosarcoma Risk: In studies, abaloparatide was associated with an increased incidence of osteosarcoma in a rat population. It is unknown whether Tymlos increases the risk of osteosarcoma in humans. Tymlos should not be used in patients with a history of bone sarcoma or other bone malignancies or in patients with skeletal metastases. Careful consideration should be given to the benefits and risks before initiating treatment, especially in patients with other risk factors for bone sarcoma [1].
Cardiovascular Safety: In a clinical trial, a higher incidence of MIs was observed in patients treated with abaloparatide compared to placebo. In patients with moderate renal impairment, changes in QTc interval were observed. Tymlos should be used with caution in patients with pre-existing cardiovascular disease.
Hypercalcemia: Tymlos may cause hypercalcemia. Before initiating Tymlos, serum calcium should be corrected. If hypercalcemia occurs, treatment with Tymlos should be discontinued [1].
Urinary Tract Infections: Postmarketing reports of urinary tract infections (UTIs), including some cases of pyelonephritis and sepsis, have been associated with Tymlos use. If a UTI is suspected, Tymlos should be discontinued and appropriate treatment initiated.
What are the common side effects of Tymlos?
The most common adverse reactions observed in clinical trials of Tymlos included injection site reactions, nausea, headache, fatigue, and hypercalcemia [1].
How does Tymlos compare to other osteoporosis medications?
Tymlos, which contains abaloparatide, is a parathyroid hormone analog. It works by stimulating bone formation. Other osteoporosis medications include bisphosphonates, which primarily inhibit bone resorption, and other parathyroid hormone analogs like teriparatide. Clinical studies have compared the efficacy of Tymlos to placebo and teriparatide in reducing fracture risk.
When does Tymlos patent expire?
Information regarding the patent expiration of Tymlos can be found on specialized drug patent tracking websites. For example, DrugPatentWatch.com provides data on drug patents and their expiration dates [2].
Who manufactures Tymlos?
Tymlos is manufactured by Radius Health, Inc.
What are the clinical trial results for Tymlos?
Clinical trials have demonstrated that Tymlos significantly reduces the risk of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. Studies have also shown increases in bone mineral density.
What are the regulatory approvals for Tymlos?
Tymlos has received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
---
Sources:
[1] https://www. Tymlos.com/
[2] https://drugpatentwatch.com/